| Literature DB >> 34017321 |
Christos A Christakis1, Georgia Daskalogiannis2, Anastasia Chatzaki3, Emmanouil A Markakis3, Glykeria Mermigka1, Angeliki Sagia2, Giulio Flavio Rizzo4, Vittoria Catara4, Ilias Lagkouvardos5, David J Studholme6, Panagiotis F Sarris1,2,6.
Abstract
Halophytic endophytes potentially contribute to the host's adaptation to adverse environments, improving its tolerance against various biotic and abiotic stresses. Here, we identified the culturable endophytic bacteria of three crop wild relative (CWR) halophytes: Cakile maritima, Matthiola tricuspidata, and Crithmum maritimum. In the present study, the potential of these isolates to improve crop adaptations to various stresses was investigated, using both in vitro and in-planta approaches. Endophytic isolates were identified by their 16S rRNA gene sequence and evaluated for their ability to: grow in vitro in high levels of NaCl; inhibit the growth of the economically important phytopathogens Verticillium dahliae, Ralstonia solanacearum, and Clavibacter michiganensis and the human pathogen Aspergillus fumigatus; provide salt tolerance in-planta; and provide growth promoting effect in-planta. Genomes of selected isolates were sequenced. In total, 115 endophytic isolates were identified. At least 16 isolates demonstrated growth under increased salinity, plant growth promotion and phytopathogen antagonistic activity. Three showed in-planta suppression of Verticillium growth. Furthermore, representatives of three novel species were identified: two Pseudomonas species and one Arthrobacter. This study provides proof-of-concept that the endophytes from CWR halophytes can be used as "bio-inoculants," for the enhancement of growth and stress tolerance in crops, including the high-salinity stress.Entities:
Keywords: bio-inoculants; biocontrol; biofertilizers; endophytes; growth-promotion; halophytes; salinity tolerance; stress tolerance
Year: 2021 PMID: 34017321 PMCID: PMC8129196 DOI: 10.3389/fmicb.2021.681567
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
FIGURE 1Abundance of genera of bacterial isolates obtained from leaves and roots of Matthiola tricuspidata, Crithmum maritimuma, and Cakile maritima plants.
FIGURE 2In vitro growth inhibition experiments: against phytopathogenic bacteria Ralstonia solanacearum or Clavibacter michiganensis (A), against phytopathogenic fungus Verticillium dahliae (B) and against human pathogenic fungus Aspergillus fumigatus (C). Representative experiments are shown to display their “weak” (A1–C1), “medium” (A2–C2), or “strong” (A3–C3) inhibitory activity.
In-planta plant growth promotion and salt tolerance assays in Arabidopsis thaliana plants. For the salt tolerance assays plants were watered with and without NaCl solution every 2-3 days and fresh and dry plant weight was measured.
| CML12 | 0.410 | 0.029 | 1.500 | 0.109 | 0.246 | 0.034 | 0.307 | 0.038 | |
| CML15 | 0.204 | 0.025 | 1.240 | 0.135 | 0.309 | 0.052 | 0.347 | 0.060 | |
| CMR13 | 0.144 | 0.022 | 1.134 | 0.170 | 0.239 | 0.032 | 0.252 | 0.034 | |
| CrL01 | 0.541 | 0.053 | 1.761 | 0.168 | 0.147 | 0.031 | 0.186 | 0.041 | |
| CrL04 | 0.149 | 0.019 | 1.169 | 0.137 | 0.197 | 0.031 | 0.203 | 0.032 | |
| CrL11 | 0.242 | 0.026 | 1.244 | 0.130 | 0.236 | 0.034 | 0.217 | 0.030 | |
| CrR16 | 0.277 | 0.026 | 1.307 | 0.123 | 0.165 | 0.031 | 0.194 | 0.035 | |
| CrR22 | 0.094 | 0.016 | 1.003 | 0.150 | 0.275 | 0.042 | 0.297 | 0.045 | |
| CrR23 | 0.170 | 0.023 | 1.173 | 0.148 | 0.103 | 0.026 | 0.127 | 0.030 | |
| MTL01 | 0.113 | 0.017 | 1.132 | 0.145 | 0.202 | 0.037 | 0.213 | 0.038 | |
| MTR05 | 0.169 | 0.028 | 1.139 | 0.184 | 0.322 | 0.056 | 0.364 | 0.062 | |
| MTR27 | 0.114 | 0.015 | 1.119 | 0.150 | 0.213 | 0.033 | 0.209 | 0.033 | |
| Control | 0.110 | 0.017 | 1.111 | 0.171 | 0.235 | 0.034 | 0.216 | 0.031 | |
| Control H2O | 0.156 | 0.023 | 1.056 | 0.089 | 1.266 | 0.094 | 1.212 | 0.088 | |
| Control Salt | 0.250 | 0.034 | 0.221 | 0.029 | |||||
Values of fungal parameters of Verticillium dahliae treated with 16 different bacterial isolates (CrR14, CrR18, CrR04, MTR12, MTR18, CM0R1, CMR03, CML04, CMR25, MTR17a, MTR17d, MTR17f, MTR17g, MTR17h, MTR17b, MTR17c) and Trichoderma harzianum strain T22 in dual-culture and dual-plate assays. Values were estimated as the percentage of inhibition compared to control (V.d.).
| V.d. | 0.00 h | 0.00 e | 0.00 d | 0.00 f | 0.00 cde | 0.00 b | 0.00 de | 0.00 cde |
| V.d. + CrR14 | 52.92 c | 70.87 cd | 25.21 abc | 68.98 ab | 8.75 c | 83.08 a | 18.46 abcd | 13.56 bcd |
| V.d. + CrR18 | 76.78 b | 57.11 d | 33.53 a | 52.41 bcde | −1.97 cde | 79.68 a | 22.33 ab | 24.99 cde |
| V.d. + CrR04 | 45.73 cd | 74.30 bc | 20.56 abcd | 47.88 bcde | 4.66 cd | 21.84 ab | 21.09 abc | 71.91 ab |
| V.d. + MTR12 | 23.97 ef | 92.94 a | 22.92 abc | 26.65 cdef | −3.83 cde | 82.75 a | 25.99 a | −20.10 cde |
| V.d. + MTR18 | 33.95 de | 89.36 bc | 23.49 abc | 34.23 bcdef | −2.78 cde | 83.13 a | 30.95 a | −1.86 cde |
| V.d. + CMR01 | 21.91 ef | 81.46 abc | 30.26 ab | 60.41 abcd | −1.54 cde | 84.81 a | 30.72 a | −25.08 cde |
| V.d. + CMR03 | 27.22 ef | 88.34 abc | 17.56 abcd | 47.42 bcde | 7.70 c | 56.63 ab | 21.45 abc | 42.98 abc |
| V.d. + CML04 | 59.69 c | 70.31 cd | 18.10 abcd | 65.11 abc | −1.10 cde | 78.68 a | 28.22 a | −32.44 de |
| V.d. + CMR25 | 23.15 ef | 79.00 abc | 13.67 abcd | 23.94 def | −3.58 cde | 70.63 ab | 17.55 abcd | −12.64 cde |
| V.d. + MTR17a | 45.22 cd | 82.66 abc | 6.89 cd | 22.63 def | −8.86 de | −100.42 c | −5.11 e | −43.35 cd |
| V.d. + MTR17d | 45.85 cd | 83.99 abc | 5.56 ab | 32.93 bcdef | 3.31 cd | 74.61 ab | −3.78 e | −2.18 de |
| V.d. + MTR17f | 51.46 c | 74.21 bc | 10.89 bcd | 18.77 ab | −16.21 e | 77.33 ab | 1.56 de | −60.99 e |
| V.d. + MTR17g | 16.75 fg | 5.29 e | 21.33 abc | 62.41 abcd | −4.50 cde | 38.33 ab | 3.00 cde | −2.99 cde |
| V.d. + MTR17h | 2.86 gh | 70.53 cd | 5.59 cd | −67.79 g | 55.99 b | −116.97 c | 5.59 bcde | −298.98 f |
| V.d. + MTR17b | 49.02 cd | 81.79 abc | 0.58 d | 22.91 def | 74.57 a | −120.55 c | 0.58 de | 97.83 a |
| V.d. + MTR17c | 60.21 c | 91.26 a | 7.60 cd | 24.02 def | 69.06 ab | −88.87 c | 6.35 bcde | 99.28 a |
| V.d. + TRIANUM-P | 95.79 a | 79.46 abc | nm | 98.91 a | ne | ne | ne | ne |
FIGURE 3Verticillium wilt disease severity index on eggplant treated with various bacterial isolates at 12, 14, 18, 21, and 24 days post inoculation with Verticillium dahliae conidial suspension (20 mL of 5 × 106 conidia mL–1). Each column represents the mean of 21 plants after combining the results of 3 replicated experiments (experiment I). Columns at each observation time point followed by the same letter are not significantly different according to Tukey’s HSD test at P ≤ 0.05. Vertical bars indicate standard errors.
FIGURE 4Verticillium wilt disease severity index on eggplant treated with various bacterial isolates and the commercial biofungicide TRIANUM-P (Koppert B.V. Hellas) at 12, 14, 16, 19, 23, 26, 28, and 30 days post inoculation with Verticillium dahliae conidial suspension (20 mL of 5 × 106 conidia mL–1). Each column represents the mean of 21 plants after combining the results of 3 replicated experiments (experiment II). Columns at each observation time point followed by the same letter are not significantly different according to Tukey’s HSD test at P ≤ 0.05. Vertical bars indicate standard errors.
Values (± standard errors) of disease parameters for eggplants inoculated with V. dahliae and treated with different bacterial isolates and TRIANUM-P (CrR14, CrR18, CrR04, MTR12, MTR18, CMR01, CMR03, CML04, CMR25 in experiment I, and MTR17a, MTR17d, MTR17f, MTR17g, MTR17h, MTR17b, MTR17c, TRIANUM-P in experiment II) or not (C−, V.d.).
| C− | 0.00 ± 0.00b | 0.00 ± 0.00c | 0.00 ± 0.00c | 0.00 ± 0.00c | 0.00 ± 0.00b | |
| V.d. | 100.00 ± 0.00a | 91.00 ± 1.91 | 100.00 ± 0.00a | 42.36 ± 2.08a | 0.55 ± 0.07 | |
| V.d. + CrR14 | 100.00 ± 0.00a | 92.74 ± 2.21 | 95.24 ± 4.76a | 42.54 ± 2.62a | 0.65 ± 0.05a | |
| V.d. + CrR18 | 100.00 ± 0.00a | 95.50 ± 1.80a | 90.48 ± 6.15 | 39.19 ± 1.99 | 0.55 ± 0.08 | |
| V.d. + CrR04 | 100.00 ± 0.00a | 93.40 ± 2.99a | 78.57 ± 7.70 | 39.84 ± 2.18 | 0.60 ± 0.05 | |
| Experiment I | V.d. + MTR12 | 100.00 ± 0.00a | 88.29 ± 2.74 | 80.95 ± 9.91 | 33.86 ± 2.59 | 0.80 ± 0.07a |
| V.d. + MTR18 | 100.00 ± 0.00a | 80.19 ± 4.75 | 71.43 ± 8.69 | 31.67 ± 3.02b | 0.55 ± 0.05 | |
| V.d. + CMR01 | 100.00 ± 0.00a | 78.79 ± 2.85c | 52.38 ± 14.29b | 30.72 ± 2.18b | 0.55 ± 0.08 | |
| V.d. + CMR03 | 100.00 ± 0.00a | 86.07 ± 2.71 | 66.67 ± 14.55 | 32.25 ± 1.47b | 0.65 ± 0.08a | |
| V.d. + CML04 | 100.00 ± 0.00a | 85.82 ± 3.34 | 69.05 ± 5.67 | 37.91 ± 2.00 | 0.65 ± 0.05a | |
| V.d. + CMR25 | 100.00 ± 0.00a | 91.17 ± 2.37 | 80.95 ± 9.91 | 35.71 ± 1.46 | 0.85 ± 0.03a | |
| C− | 0.00 ± 0.00c | 0.00 ± 0.00c | 0.00 ± 0.00b | 0.00 ± 0.00 | 0.00 ± 0.00b | |
| V.d. | 90.48 ± 6.15 | 68.49 ± 5.43a | 47.62 ± 9.91a | 26.76 ± 2.95a | 0.53 ± 0.05a | |
| V.d. + MTR17a | 71.43 ± 15.31 | 50.21 ± 7.88 | 33.33 ± 10.29 | 15.05 ± 2.81 | 0.20 ± 0.09 | |
| V.d. + MTR17d | 95.24 ± 4.76a | 70.22 ± 3.93a | 23.81 ± 14.02 | 23.04 ± 2.20 | 0.40 ± 0.20 | |
| Experiment I I | V.d. + MTR17f | 85.71 ± 9.91 | 64.79 ± 6.12a | 33.33 ± 14.51 | 22.95 ± 2.67 | 0.38 ± 0.17 |
| V.d. + MTR17g | 80.95 ± 6.73 | 58.36 ± 6.85 | 38.10 ± 11.34 | 16.81 ± 2.84 | 0.27 ± 0.12 | |
| V.d. + MTR17h | 52.38 ± 12.30b | 35.15 ± 7.58b | 4.76 ± 4.76b | 10.51 ± 2.58 | 0.10 ± 0.04b | |
| V.d. + MTR17b | 80.95 ± 9.91 | 57.05 ± 6.52 | 19.05 ± 6.73 | 14.85 ± 2.03 | 0.40 ± 0.18 | |
| V.d. + MTR17c | 76.19 ± 9.52 | 49.66 ± 7.35 | 23.81 ± 6.15 | 11.73 ± 2.35c | 0.13 ± 0.06 | |
| V.d. + TRIANUM-P | 52.38 ± 6.74b | 33.45 ± 7.44b | 4.76 ± 4.76b | 7.88 ± 1.94 | 0.20 ± 0.09 | |
Number of genes related to Virulence, Disease and Defense features of the three new bacterial species identified in this study. The genome analysis and the annotation was performed using the RAST genome annotation software.
| Mercury resistance operon | 1 | 0 | 0 | 0 |
| Copper homeostasis | 6 | 25 | 18 | 18 |
| Cobalt-zinc-cadmium resistance | 4 | 12 | 17 | 16 |
| Resistance to fluoroquinolones | 2 | 5 | 2 | 5 |
| Copper homeostasis: copper tolerance | 2 | 2 | 2 | 2 |
| Beta-lactamase | 1 | 0 | 2 | 1 |
| Mercuric reductase | 3 | 3 | 0 | 0 |
| Multidrug Resistance Efflux Pumps | 0 | 7 | 0 | 0 |
| Resistance to chromium compounds | 0 | 1 | 1 | 3 |
| Mycobacterium virulence operon involved in protein synthesis (SSU ribosomal proteins) | 6 | 9 | 6 | 7 |
| Mycobacterium virulence operon involved in DNA transcription | 3 | 6 | 2 | 4 |
| Mycobacterium virulence operon possibly involved in quinolinate biosynthesis | 3 | 3 | 3 | 3 |
| Listeria surface proteins: Internalin-like proteins | 4 | 0 | 0 | 0 |
| Mycobacterium virulence operon involved in protein synthesis (LSU ribosomal proteins) | 3 | 3 | 3 | 3 |
| Tolerance to colicin E2 | 0 | 2 | 2 | 2 |
| Protein secretion system, Type II (Widespread colonization island) | 11 | 14 | 10 | 10 |
| Protein secretion system, Type II (General Secretion Pathway) | 0 | 15 | 0 | 0 |
| Protein secretion system, Type V (Two partner secretion pathway–TPS) | 0 | 4 | 0 | 0 |
| Protein secretion system, Type I | 0 | 0 | 29 | 22 |
| Protein secretion system, Type III | 0 | 0 | 0 | 0 |
| Protein secretion system, Type VI | 0 | 0 | 0 | 0 |
| Protein and nucleoprotein secretion system, Type IV (Type IV pilus) | 0 | 28 | 22 | 20 |
| Protein and nucleoprotein secretion system, Type IV (Conjugative transfer) | 0 | 12 | 0 | 0 |
| Protein secretion system, Type VII (Chaperone/Usher pathway, CU) | 0 | 0 | 13 | 12 |
| Twin-arginine translocation system | 3 | 4 | 7 | 7 |
| Protein secretion system, Type VIII (Extracellular nucleation/precipitation pathway, ENP) | 0 | 0 | 5 | 12 |
FIGURE 5Molecular phylogenetic analysis of Arthrobacter recA-gyrB genes by Maximum Likelihood method. Phylogenetic tree is drawn to scale, with branch lengths measured in the number of substitutions per site.
FIGURE 6Molecular Phylogenetic analysis of the recA-gyrB genes from Pseudomonads belonging to P. putida and P. mendocina groups by Maximum Likelihood method. The tree with the highest log likelihood (–7831.6808) is shown. The tree is drawn to scale, with branch lengths measured in the number of substitutions per site.
FIGURE 7A graphical abstract describing the steps of the procedure we followed to accomplish this work.